ライフサイエンスコーパス: seroprotection

1 ed anti-rubella virus immunoglobulin G (IgG) seroprotection.

2 dults aged >/= 80 years), among whom 80% had seroprotection.

3 TIV), with or without adjuvant, may increase seroprotection.

4 years, half of teens and adults showed H3N2v seroprotection.

5 lations of TIV do not substantially increase seroprotection.

6 A similar trend was identified for seroprotection.

7 with regard to an absolute titer indicating seroprotection.

8 ization opportunity window and could improve seroprotection.

9 d in a meta-analysis to provide estimates of seroprotection 2 and 5 years after the last vaccine admi

10 Two definitions of seroprotection (40 hemagglutination units (HAU) and 160

11 ificantly lower in PHIV children for measles seroprotection (57% [95% confidence interval {CI}, 52%-6

12 primary efficacy parameter was the degree of seroprotection 6 or 7 months (26 +/- 2 weeks) after begi

13 52%-62%] vs 99% [95% CI, 96%-100%]), rubella seroprotection (65% [95% CI, 60%-70%] vs 98% [95% CI, 95

14 There was evidence of transplacental seroprotection 8 days after maternal immunization (77.9%

15 -microg regimen elicited the highest rate of seroprotection (96.2%), with a geometric mean titer of a

16 acking seroprotection at entry, 66% attained seroprotection after dose 1 and 75% after dose 2.

17 a "complete response" (both seroresponse and seroprotection) after first vaccination was associated w

18 g children aged <5 years in 2013, among whom seroprotection again decreased to <20%.

19 es were completion of the 3-dose vaccine and seroprotection against hepatitis B virus (HBV).

20 inst influenza A viruses (P < .001), greater seroprotection against influenza A/H1N1 (P = .01), and g

21 day 28 and percentages of seroconversion and seroprotection, all determined by haemagglutination inhi

22 Knowledge of the age-specific prevalence of seroprotection and incidence of seroconversion infection

23 Measles revaccination induced high rates of seroprotection and memory in children receiving HAART.

24 e reduction neutralization assay and rubella seroprotection and mumps seropositivity by enzyme immuno

25 Predictors of rubella seroprotection and mumps seropositivity were similar.

26 S aureus colonization experienced (1) lower seroprotection and seroconversion rates and lower hemagg

27 Seroprotection and seroresponse (>/=4-fold rise) occurre

28 Furthermore, seroprotection at 10 weeks was higher in the booster gro

29 Seroprotection at 6 months was greater for those on the

30 Of women lacking seroprotection at entry, 66% attained seroprotection aft

31 Among participants who lacked seroprotection at entry, a "complete response" (both ser

32 ears later, 85% demonstrated memory based on seroprotection before or 7 days after vaccination.

33 red age-related cross-sectional estimates of seroprotection before the pandemic (during 2009) and aft

34 logic specimen was used to determine measles seroprotection by plaque reduction neutralization assay

35 n the 10(11) VP cohort (89%; 67-99) achieved seroprotection compared with four of 22 placebo recipien

36 , reflecting a mirror image of the age-based seroprotection data.

37 ded in HIV-infected patients to estimate how seroprotection decreases over time in those who initiall

38 The primary end point was the rate of seroprotection, defined as antibody titers of 1:40 or gr

39 Conversely, postpandemic seroprotection followed a U-shaped distribution, with de

40 ith baseline titers had significantly higher seroprotection for the 2009-H1N1 strain (100% vs. 73%, r

41 Cumulative HBV seroprotection (>/=10 mIU/mL) was gained within 12 month

42 Children in all groups had evidence of seroprotection (>10 mIU/mL) at 1 month after the second

43 were classified as responders if, by week 3, seroprotection guidelines were met.

44 aforementioned age groups, respectively, and seroprotection (HAI titers >/= 40) was shown in 79.6%, 8

45 in the proportion of participants achieving seroprotection (hemagglutination-inhibition antibody tit

46 Seroprotection (HI titre >/=1:40) was detected in 58 (75

47 ted persons reach higher levels of influenza seroprotection if vaccinated with the high-dose trivalen

48 ansplacental antibody transfer occurred, but seroprotection in infants waned rapidly.

49 mproved the cumulative prediction of measles seroprotection in PHIV.

50 Seroprotection increased to 89% 8 weeks postvaccination,

51 Of those lacking seroresponse (n = 43) or seroprotection (n = 37) after the first vaccination, 46.

52 Seroprotection persisted in most women postpartum.

53 Measles seroprotection persisted through age 24 months among HIV

54 Frequencies of seroprotection pre-vaccination and vaccine responsivenes

55 Baseline WT seroprotection ranged between 78.7% and 87.2%; all subje

56 4 WT strains at 28 days and 6 months; year 5 seroprotection ranged between 95.7% and 97.9%.

57 The primary outcome was seroprotection rate (anti-influenza antibody titers by h

58 mune responses in subjects aged 18-64 years (seroprotection rate [SPR], 97.2%; seroconversion rate [S

59 the 98.3% confidence interval for the day 42 seroprotection rate was >/=70%, thus fulfilling the US a

60 lations, seroconversion rates were >/=85.7%, seroprotection rates >/=91.1%, and geometric mean titers

61 After vaccination, HAI titers and seroprotection rates (the percentage of participants wit

62 The seroprotection rates after vaccination were higher in th

63 Primary immunogenicity outcomes were seroprotection rates and MMR-specific antibody concentra

64 However, the seroprotection rates are disappointingly low when 160 HA

65 At 6 months after immunization, seroprotection rates at 40 HAU (95% healthy and 97% lung

66 Seroprotection rates do not differ between healthy and t

67 Seroprotection rates for influenza B, H1N1, and H3N2 wer

68 he 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana.

69 Seroprotection rates were also higher for those who rece

70 At 12 months, seroprotection rates were higher in revaccinated patient

71 Geometric mean titers and seroprotection rates were similar between groups.

72 Seroconversion and seroprotection rates were similar in the two groups on d

73 GMTs, seroprotection rates, and seroconversion rates were comp

74 c mean titers (GMTs) between the 2 vaccines, seroprotection rates, and seroconversion rates.

75 study vaccination was associated with higher seroprotection rates, greater antibody concentrations, a

76 comparing changes in the seroconversion and seroprotection rates.

77 on, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccinati

78 suggest that a two-dose regimen can achieve seroprotection similar to that of the three-dose regimen

79 HIV-infected children demonstrated seroprotection through age 12 months, but this was not s

80 eipt of 2 doses, 61.17% of subjects retained seroprotection titers at 24 months, and immunogenicity c

81 With a single dose of JENVAC, seroprotection titers lasted at least 12 months in >80%

82 In 212 evaluable patients (105 IM, 107 ID), seroprotection to H1N1, H3N2 and B strains was 70.5%, 63

83 trieved from the literature, the decrease of seroprotection was modeled with a log binomial generaliz

84 Prepandemic seroprotection was negligible except for very old adults

85 Our analyses confirmed that the duration of seroprotection was shorter in HIV-infected patients and

86 After both the doses, seroconversion and seroprotection were >90% for JENVAC.

87 For SA-14-14-2, seroconversion and seroprotection were 57.69% and 77.56%, respectively, on

88 Seroprevalence and seroprotection were defined as an HI titer of >/=40, and

89 participants who seroconverted and achieved seroprotection were similar between groups.

90 Pooled odds of seroconversion and seroprotection were typically lower in HIV-positive pati